Research graph
References from Adverse event reporting signals for SGLT-2 inhibitor–metformin combination therapy: a disproportionality analysis of the FAERS database. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
10.1016/s0140-6736(23)01301-6 · 2023 · External reference
Therapeutic potential of traditional Chinese medicine and mechanisms for the treatment of type 2 diabetes mellitus
10.1186/s13020-025-01222-x · 2025 · External reference
Diabetes and thrombosis: a central role for vascular oxidative stress
10.3390/antiox10050706 · 2021 · External reference
Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus
10.1007/s11892-022-01453-4 · 2022 · External reference
Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade
10.1016/j.biopha.2021.112138 · 2021 · External reference
Sexual hormones and diabetes: the impact of estradiol in pancreatic β cell
10.1016/bs.ircmb.2021.02.004 · 2021 · External reference
Exosomal non coding RNAs as a novel target for diabetes mellitus and its complications
10.1016/j.ncrna.2023.02.001 · 2023 · External reference
Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: consensus recommendations of a Chinese expert panel (version 2025)
10.1111/dom.70197 · 2025 · External reference
Initial pharmacological strategies in people with early type 2 diabetes mellitus: a systematic review and network meta-analysis
10.4093/dmj.2024.0660 · 2025 · External reference
Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians
10.7326/m23-2788 · 2024 · External reference
SGLT-2 inhibitors and GLP-1 receptor agonists as combination therapy in type 2 diabetes
10.1007/s11892-025-01616-z · 2026 · External reference
Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: a retrospective cohort study using the TriNetX US collaborative networks
10.1111/dom.15918 · 2024 · External reference
The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study
10.1186/s12933-025-02643-6 · 2025 · External reference
Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
10.3389/fphar.2024.1288362 · 2024 · External reference
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
10.1002/pds.668 · 2002 · External reference
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
10.1002/pds.677 · 2001 · External reference
A Bayesian neural network method for adverse drug reaction signal generation
10.1007/s002280050466 · 1998 · External reference
Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database
10.2165/00002018-200225060-00001 · 2002 · External reference
A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
10.3389/fphar.2023.1320458 · 2023 · External reference
A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
10.3389/fphar.2023.1200254 · 2023 · External reference
Comparison of data mining methodologies using Japanese spontaneous reports
10.1002/pds.964 · 2004 · External reference
Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients
10.4093/dmj.2023.0128 · 2024 · External reference
Sodium-glucose cotransporter inhibitors as antidiabetic drugs: current development and future perspectives
10.1021/acs.jmedchem.2c00867 · 2022 · External reference
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study
10.1093/ehjcvp/pvae045 · 2024 · External reference
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
10.1186/s12933-024-02491-w · 2024 · External reference
The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes
10.2337/dc21-2043 · 2022 · External reference
Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice
10.1016/j.ijbiomac.2024.130962 · 2024 · External reference
Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease
10.1016/j.pharmthera.2022.108330 · 2023 · External reference
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
10.1016/j.pharmthera.2023.108503 · 2023 · External reference
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
10.1016/s0140-6736(22)02074-8 · 2022 · External reference
Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease
10.1001/jamanetworkopen.2023.50050 · 2024 · External reference
A systematic review and meta-analysis on the safety and efficacy of sodium-glucose cotransporter 2 inhibitor use in hospitalized patients
10.2337/dc24-0946 · 2024 · External reference
Metformin: past, present, and future
10.1007/s11892-024-01539-1 · 2024 · External reference
Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis
10.1038/s41421-023-00595-3 · 2023 · External reference
Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: an observational study using data from routine care
10.1111/dom.14474 · 2021 · External reference
Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium-glucose cotransporter-2 inhibitors versus metformin: a cohort study
10.7326/m21-4012 · 2022 · External reference
Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review
10.1007/s11892-024-01537-3 · 2024 · External reference
Efficacy of weight-lowering agents on fat distribution: a systematic review and network meta-analysis of randomized controlled trials
10.1111/obr.70100 · 2026 · External reference
Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: a meta-analysis
10.1111/obr.13336 · 2021 · External reference
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: from metabolic mechanisms to international guidelines
10.3390/antiox15050553 · 2026 · External reference
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
10.1186/s12933-024-02539-x · 2024 · External reference
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes
10.1111/dom.14508 · 2021 · External reference
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss
10.1038/s42255-019-0146-4 · 2019 · External reference
Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos
10.1016/j.biopha.2022.113882 · 2022 · External reference
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
10.1111/dom.14928 · 2023 · External reference
Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: a systematic review and network meta-analysis of randomized controlled trials
10.1002/dmrr.3515 · 2022 · External reference
Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database
10.3389/fimmu.2026.1769013 · 2026 · External reference
Diabetic ketoacidosis as an effect of sodium-glucose cotransporter 2 inhibitor: real world insights
10.4093/dmj.2024.0036 · 2024 · External reference
